GlassScriptPhysician profile
Anila Mustafa
NPI 1942418868
$2,746.74
in general payments reported to CMS, 2019-2025
27 companies · $1,988 in 2025
The $1,988 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $61.10 · 2021: $459 · 2022: $11.99 · 2024: $227 · 2025: $1,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,140 · Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,139.60 |
| Food and Beverage | $1,075.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,390.06 | 2025 | Minimed 780g |
| Lilly USA, LLC | $307.74 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Corcept Therapeutics | $145.85 | 2021-2025 | Korlym |
| Novo Nordisk INC | $132.26 | 2020-2025 | Ozempic |
| Amgen INC. | $129.52 | 2021-2025 | Evenity, Tepezza |
| Beta Bionics, INC. | $66.90 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amneal Pharmaceuticals LLC | $66.21 | 2021-2025 | Unithroid |
| Abbott Laboratories | $62.63 | 2021-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $47.44 | 2021 | |
| Recordati_rare_diseases_inc. | $45.90 | 2025 | Isturisa |
| Echosens North America, INC. | $40.40 | 2025 | Fibroscan |
| Tandem Diabetes Care, INC. | $36.86 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $33.93 | 2021 | |
| Insulet Corporation | $28.19 | 2025 | Omnipod |
| Soleno Therapeutics, INC. | $25.87 | 2025 | Vykat Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $22.87 | 2021 | |
| Abbvie INC. | $19.78 | 2021 | |
| Dexcom, INC. | $18.03 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $17.92 | 2024 | Recorlev |
| Currax Pharmaceuticals LLC | $17.84 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.87 | 2024 | |
| Ibsa Pharma INC. | $14.17 | 2020 | |
| Medtronic Minimed, INC. | $13.27 | 2020 | |
| Grt US Holding, INC. | $12.56 | 2021 | |
| Mannkind Corporation | $12.39 | 2020 | |
| Novartis Pharmaceuticals Corporation | $11.99 | 2022 | |
| Cequr Corporation | $10.29 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anila Mustafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.